by Impulse Dynamics | May 10, 2018 | Press Releases
NEWS FIX-HF-5C Late-Breaking Clinical Trial Data Presented at HRS 2018 with Simultaneous Publication in the JACC: Heart Failure Orangeburg, New York, May 10, 2018 – Impulse Dynamics (USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of...
by Impulse Dynamics | Dec 18, 2017 | Press Releases
NEWS The CFDA Approves Impulse Dynamics’ Optimizer System for Treatment of Chronic Heart Failure in China Orangeburg, New York & Stuttgart, Germany. December 18, 2017 – The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system...
by Impulse Dynamics | Aug 7, 2017 | Press Releases
NEWS Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study. Orangeburg, New York. August 7, 2017 – Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a...
by Impulse Dynamics | May 11, 2017 | Press Releases
NEWS Impulse Dynamics Completes $45 million Financing Round Stuttgart, May 11, 2017 – Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has...
by Impulse Dynamics | Mar 3, 2017 | Press Releases
NEWS Impulse Dynamics Successfully Launches the Optimizer Smart Device for Heart Failure Treatment in Europe Impulse Dynamics has launched the next generation of its Optimizer device, the Optimizer Smart, in Europe after it received the CE mark. The Optimizer Smart is...
by Impulse Dynamics | Sep 12, 2016 | Press Releases
NEWS Impulse Dynamics Recognized with Frost & Sullivan’s 2016 New Product Innovation Award September 12, 2016 – Impulse Dynamics, developer of the Optimizer™ IVs implantable device for the treatment of Chronic Heart Failure (CHF), is the recipient of the...
Recent Comments